US09627Y1091 - Common Stock
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective May 1, 2024, the Compensation Committee of Blueprint Medicines'...
BPMC stock results show that Blueprint Medicines beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on...
/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced it will launch a webcast series to provide scientific perspectives and showcase...
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective April 1, 2024, the Compensation Committee of Blueprint...
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective March 1, 2024, the Compensation Committee of Blueprint...
-- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable safety supporting long-term treatment, consistent with...
The company reported better-than-expected sales of its rare-disease drug, but there's one drawback in its report.
-- Achieved $204.2 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues in 2023, including $71.0 million in the fourth quarter -- -- Anticipate...
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective February 1, 2024, the Compensation Committee of Blueprint...
/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on...
On the back of recent deals involving big pharma, Barron’s issued positive remarks on a possible acceleration of biotech M&A activity on Tuesday. Read more here.
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective January 1, 2023, the Compensation Committee of Blueprint...
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of...
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data showcasing its commitment to advance the scientific understanding and...
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective December 1, 2023, the Compensation Committee of Blueprint...
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that company management will participate virtually in a fireside chat at the JMP...
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European...
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective November 1, 2023, the Compensation Committee of Blueprint...